BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Milich DR, Chen M, Schödel F, Peterson DL, Jones JE, Hughes JL. Role of B cells in antigen presentation of the hepatitis B core. Proc Natl Acad Sci U S A 1997;94:14648-53. [PMID: 9405667 DOI: 10.1073/pnas.94.26.14648] [Cited by in Crossref: 148] [Cited by in F6Publishing: 139] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines. 2007;6:381-390. [PMID: 17542753 DOI: 10.1586/14760584.6.3.381] [Cited by in Crossref: 210] [Cited by in F6Publishing: 192] [Article Influence: 15.0] [Reference Citation Analysis]
2 Harris A, Belnap DM, Watts NR, Conway JF, Cheng N, Stahl SJ, Vethanayagam JG, Wingfield PT, Steven AC. Epitope diversity of hepatitis B virus capsids: quasi-equivalent variations in spike epitopes and binding of different antibodies to the same epitope. J Mol Biol. 2006;355:562-576. [PMID: 16309704 DOI: 10.1016/j.jmb.2005.10.035] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
3 Billaud JN, Peterson D, Schödel F, Chen A, Sallberg M, Garduno F, Goldstein P, McDowell W, Hughes J, Jones J, Milich D. Comparative antigenicity and immunogenicity of hepadnavirus core proteins. J Virol 2005;79:13641-55. [PMID: 16227284 DOI: 10.1128/JVI.79.21.13641-13655.2005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wu T, Wu XL, Ou SH, Lin CX, Cheng T, Li SW, Ng MH, Zhang J, Xia NS. Difference of T cell and B cell activation in two homologous proteins with similar antigenicity but great distinct immunogenicity. Mol Immunol 2007;44:3261-6. [PMID: 17408743 DOI: 10.1016/j.molimm.2007.01.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
5 Chen M, Sällberg M, Thung SN, Hughes J, Jones J, Milich DR. Nondeletional T-cell receptor transgenic mice: model for the CD4(+) T-cell repertoire in chronic hepatitis B virus infection. J Virol. 2000;74:7587-7599. [PMID: 10906213 DOI: 10.1128/JVI.74.16.7587-7599.2000] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
6 Fehr T, Skrastina D, Pumpens P, Zinkernagel RM. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc Natl Acad Sci USA. 1998;95:9477-9481. [PMID: 9689105 DOI: 10.1073/pnas.95.16.9477] [Cited by in Crossref: 126] [Cited by in F6Publishing: 116] [Article Influence: 5.5] [Reference Citation Analysis]
7 Bhukya PL, C VK, Lole KS. Transcriptome analysis of hepatoma cells transfected with Basal Core Promoter (BCP) and Pre-Core (PC) mutant hepatitis B virus full genome construct. J Gen Virol 2021;102. [PMID: 33595430 DOI: 10.1099/jgv.0.001568] [Reference Citation Analysis]
8 Kramvis A, Kostaki EG, Hatzakis A, Paraskevis D. Immunomodulatory Function of HBeAg Related to Short-Sighted Evolution, Transmissibility, and Clinical Manifestation of Hepatitis B Virus. Front Microbiol. 2018;9:2521. [PMID: 30405578 DOI: 10.3389/fmicb.2018.02521] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
9 Dawood A, Abdul Basit S, Jayaraj M, Gish RG. Drugs in Development for Hepatitis B. Drugs 2017;77:1263-80. [PMID: 28660478 DOI: 10.1007/s40265-017-0769-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
10 Han Q, Yang C, Li N, Li F, Sang J, Lv Y, Zhao W, Li C, Liu Z. Association of genetic variation in B-cell activating factor with chronic hepatitis B virus infection. Immunol Lett 2017;188:53-8. [PMID: 28627389 DOI: 10.1016/j.imlet.2017.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Yang C, Li N, Wang Y, Zhang P, Zhu Q, Li F, Han Q, Lv Y, Yu L, Wei P, Liu Z. Serum levels of B-cell activating factor in chronic hepatitis B virus infection: association with clinical diseases. J Interferon Cytokine Res 2014;34:787-94. [PMID: 24811691 DOI: 10.1089/jir.2014.0032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
12 Fu TM, Grimm KM, Citron MP, Freed DC, Fan J, Keller PM, Shiver JW, Liang X, Joyce JG. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009;27:1440-7. [PMID: 19146898 DOI: 10.1016/j.vaccine.2008.12.034] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 5.8] [Reference Citation Analysis]
13 Henningsson F, Ding Z, Dahlin JS, Linkevicius M, Carlsson F, Grönvik KO, Hallgren J, Heyman B. IgE-mediated enhancement of CD4+ T cell responses in mice requires antigen presentation by CD11c+ cells and not by B cells. PLoS One 2011;6:e21760. [PMID: 21765910 DOI: 10.1371/journal.pone.0021760] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
14 Zhou G, Ma Y, Jia P, Guan Q, Uzonna JE, Peng Z. Enhancement of IL-10 bioactivity using an IL-10 peptide-based vaccine exacerbates Leishmania major infection and improves airway inflammation in mice. Vaccine 2010;28:1838-46. [PMID: 20005853 DOI: 10.1016/j.vaccine.2009.11.081] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
15 Lazdina U, Cao T, Steinbergs J, Alheim M, Pumpens P, Peterson DL, Milich DR, Leroux-Roels G, Sällberg M. Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells. J Virol. 2001;75:6367-6374. [PMID: 11413303 DOI: 10.1128/jvi.75.14.6367-6374.2001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
16 Whitacre DC, Lee BO, Milich DR. Use of hepadnavirus core proteins as vaccine platforms. Expert Rev Vaccines. 2009;8:1565-1573. [PMID: 19863249 DOI: 10.1586/erv.09.121] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
17 Li R, Patterson KR, Bar-Or A. Reassessing B cell contributions in multiple sclerosis. Nat Immunol 2018;19:696-707. [PMID: 29925992 DOI: 10.1038/s41590-018-0135-x] [Cited by in Crossref: 144] [Cited by in F6Publishing: 125] [Article Influence: 48.0] [Reference Citation Analysis]
18 Nardelli-Haefliger D, Benyacoub J, Lemoine R, Hopkins-Donaldson S, Potts A, Hartman F, Kraehenbuhl JP, De Grandi P. Nasal vaccination with attenuated Salmonella typhimurium strains expressing the Hepatitis B nucleocapsid: dose response analysis. Vaccine. 2001;19:2854-2861. [PMID: 11282196 DOI: 10.1016/s0264-410x(01)00009-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ma Y, Ma AG, Peng Z. A potential immunotherapy approach: mucosal immunization with an IL-13 peptide-based virus-like particle vaccine in a mouse asthma model. Vaccine 2007;25:8091-9. [PMID: 17935839 DOI: 10.1016/j.vaccine.2007.09.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
20 Malik IR, Chen A, Brass A, Ahlén G, Rahman M, Sällberg M, Qureshi JA, Frelin L. A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates HBcAg-specific T cells and preS1-specific antibodies. Scandinavian Journal of Infectious Diseases 2011;44:55-9. [DOI: 10.3109/00365548.2011.608711] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
21 Alexopoulou A, Baltayiannis G, Eroglu C, Nastos T, Dourakis SP, Archimandritis AJ, Karayiannis P. Core mutations in patients with acute episodes of chronic HBV infection are associated with the emergence of new immune recognition sites and the development of high IgM anti-HBc index values. J Med Virol. 2009;81:34-41. [PMID: 19031457 DOI: 10.1002/jmv.21337] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
22 Caldeira Jdo C, Medford A, Kines RC, Lino CA, Schiller JT, Chackerian B, Peabody DS. Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 2010;28:4384-93. [PMID: 20434554 DOI: 10.1016/j.vaccine.2010.04.049] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 6.3] [Reference Citation Analysis]
23 Li Q, Wang J, Islam H, Kirschning C, Lu H, Hoffmann D, Dittmer U, Lu M. Hepatitis B virus particles activate B cells through the TLR2-MyD88-mTOR axis. Cell Death Dis 2021;12:34. [PMID: 33414473 DOI: 10.1038/s41419-020-03284-1] [Reference Citation Analysis]
24 Kratz PA, Böttcher B, Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci USA. 1999;96:1915-1920. [PMID: 10051569 DOI: 10.1073/pnas.96.5.1915] [Cited by in Crossref: 192] [Cited by in F6Publishing: 179] [Article Influence: 8.7] [Reference Citation Analysis]
25 Sominskaya I, Skrastina D, Petrovskis I, Dishlers A, Berza I, Mihailova M, Jansons J, Akopjana I, Stahovska I, Dreilina D, Ose V, Pumpens P. A VLP library of C-terminally truncated Hepatitis B core proteins: correlation of RNA encapsidation with a Th1/Th2 switch in the immune responses of mice. PLoS One 2013;8:e75938. [PMID: 24086668 DOI: 10.1371/journal.pone.0075938] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
26 Watelet B, Quibriac M, Rolland D, Gervasi G, Gauthier M, Jolivet M, Letourneur O. Characterization and diagnostic potential of hepatitis B virus nucleocapsid expressed in E. coli and P. pastoris. Journal of Virological Methods 2002;99:99-114. [DOI: 10.1016/s0166-0934(01)00385-8] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
27 Lazdina U, Alheim M, Nyström J, Hultgren C, Borisova G, Sominskaya I, Pumpens P, Peterson DL, Milich DR, Sällberg M. Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. J Gen Virol. 2003;84:139-146. [PMID: 12533710 DOI: 10.1099/vir.0.18678-0] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 3.4] [Reference Citation Analysis]
28 Gharibi T, Babaloo Z, Hosseini A, Marofi F, Ebrahimi-Kalan A, Jahandideh S, Baradaran B. The role of B cells in the immunopathogenesis of multiple sclerosis. Immunology 2020;160:325-35. [PMID: 32249925 DOI: 10.1111/imm.13198] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
29 Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology. 2003;38:1075-1086. [PMID: 14578844 DOI: 10.1053/jhep.2003.50453] [Cited by in Crossref: 275] [Cited by in F6Publishing: 236] [Article Influence: 15.3] [Reference Citation Analysis]
30 Watts NR, Cardone G, Vethanayagam JG, Cheng N, Hultgren C, Stahl SJ, Steven AC, Sällberg M, Wingfield PT. Non-canonical binding of an antibody resembling a naïve B cell receptor immunoglobulin to hepatitis B virus capsids. J Mol Biol 2008;379:1119-29. [PMID: 18486949 DOI: 10.1016/j.jmb.2008.04.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
31 Ng MY, Tan WS, Abdullah N, Ling TC, Tey BT. Effect of different operating modes and biomass concentrations on the recovery of recombinant hepatitis B core antigen from thermal-treated unclarified Escherichia coli feedstock. Journal of Biotechnology 2008;138:74-9. [DOI: 10.1016/j.jbiotec.2008.08.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
32 Skrastina D, Petrovskis I, Lieknina I, Bogans J, Renhofa R, Ose V, Dishlers A, Dekhtyar Y, Pumpens P. Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles. PLoS One 2014;9:e114006. [PMID: 25436773 DOI: 10.1371/journal.pone.0114006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
33 Khlaiphuengsin A, Chuaypen N, Sodsai P, Buranapraditkun S, Boonpiyathad T, Hirankarn N, Tangkijvanich P. Decreased of BAFF-R expression and B cells maturation in patients with hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2020;26:2645-56. [PMID: 32523317 DOI: 10.3748/wjg.v26.i20.2645] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Peabody DS, Manifold-Wheeler B, Medford A, Jordan SK, do Carmo Caldeira J, Chackerian B. Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. J Mol Biol 2008;380:252-63. [PMID: 18508079 DOI: 10.1016/j.jmb.2008.04.049] [Cited by in Crossref: 88] [Cited by in F6Publishing: 70] [Article Influence: 6.8] [Reference Citation Analysis]
35 Roose K, De Baets S, Schepens B, Saelens X. Hepatitis B core-based virus-like particles to present heterologous epitopes. Expert Rev Vaccines 2013;12:183-98. [PMID: 23414409 DOI: 10.1586/erv.12.150] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
36 Mastroeni P, Simmons C, Fowler R, Hormaeche CE, Dougan G. Igh-6(-/-) (B-cell-deficient) mice fail to mount solid acquired resistance to oral challenge with virulent Salmonella enterica serovar typhimurium and show impaired Th1 T-cell responses to Salmonella antigens. Infect Immun 2000;68:46-53. [PMID: 10603367 DOI: 10.1128/IAI.68.1.46-53.2000] [Cited by in Crossref: 138] [Cited by in F6Publishing: 78] [Article Influence: 6.6] [Reference Citation Analysis]
37 Papamichalis P, Alexiou A, Boulbou M, Dalekos GN, Rigopoulou EI. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy? Clin Res Hepatol Gastroenterol. 2012;36:84-93. [PMID: 21920838 DOI: 10.1016/j.clinre.2011.07.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
38 Guan ZJ, Guo B, Huo YL, Guan ZP, Wei YH. Overview of expression of hepatitis B surface antigen in transgenic plants. Vaccine 2010;28:7351-62. [PMID: 20850538 DOI: 10.1016/j.vaccine.2010.08.100] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
39 Brass A, Frelin L, Milich DR, Sällberg M, Ahlén G. Functional aspects of intrahepatic hepatitis B virus-specific T cells induced by therapeutic DNA vaccination. Mol Ther 2015;23:578-90. [PMID: 25492563 DOI: 10.1038/mt.2014.233] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
40 Bose B, Chugh DA, Kala M, Acharya SK, Khanna N, Sinha S. Characterization and molecular modeling of a highly stable anti-Hepatitis B surface antigen scFv. Mol Immunol. 2003;40:617-631. [PMID: 14597165 DOI: 10.1016/j.molimm.2003.07.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
41 Borisova G, Borschukova O, Skrastina D, Dislers A, Ose V, Pumpens P, Grens E. Behavior of a short preS1 epitope on the surface of hepatitis B core particles. Biol Chem. 1999;380:315-324. [PMID: 10223334 DOI: 10.1515/bc.1999.043] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
42 Lee BO, Tucker A, Frelin L, Sallberg M, Jones J, Peters C, Hughes J, Whitacre D, Darsow B, Peterson DL, Milich DR. Interaction of the hepatitis B core antigen and the innate immune system. J Immunol 2009;182:6670-81. [PMID: 19454661 DOI: 10.4049/jimmunol.0803683] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
43 Lee BO, Jones JE, Peters CJ, Whitacre D, Frelin L, Hughes J, Kim WK, Milich DR. Identification of a unique double-negative regulatory T-cell population. Immunology 2011;134:434-47. [PMID: 22044159 DOI: 10.1111/j.1365-2567.2011.03502.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
44 Guan Q, Weiss CR, Qing G, Ma Y, Peng Z. An IL-17 peptide-based and virus-like particle vaccine enhances the bioactivity of IL-17 in vitro and in vivo. Immunotherapy 2012;4:1799-807. [PMID: 23240747 DOI: 10.2217/imt.12.129] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
45 Döring T, Prange R. Rab33B and its autophagic Atg5/12/16L1 effector assist in hepatitis B virus naked capsid formation and release. Cell Microbiol 2015;17:747-64. [PMID: 25439980 DOI: 10.1111/cmi.12398] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
46 Schickli JH, Whitacre DC, Tang RS, Kaur J, Lawlor H, Peters CJ, Jones JE, Peterson DL, McCarthy MP, Van Nest G, Milich DR. Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge. J Clin Invest 2015;125:1637-47. [PMID: 25751145 DOI: 10.1172/JCI78450] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
47 Balmelli C, Demotz S, Acha-Orbea H, De Grandi P, Nardelli-Haefliger D. Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles. J Virol 2002;76:12596-602. [PMID: 12438585 DOI: 10.1128/jvi.76.24.12596-12602.2002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
48 Meng FP, Ding J, Yu ZC, Han QL, Guo CC, Liu N, Fan DM. Oral attenuated Salmonella typhimurium vaccine against MG7-Ag mimotope of gastric cancer. World J Gastroenterol 2005;11:1833-6. [PMID: 15793876 DOI: 10.3748/wjg.v11.i12.1833] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
49 Chackerian B, Frietze KM. Moving towards a new class of vaccines for non-infectious chronic diseases. Expert Review of Vaccines 2016;15:561-3. [DOI: 10.1586/14760584.2016.1159136] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
50 Broos K, Janssens ME, De Goeyse I, Vanlandschoot P, Leroux-Roels G, Geysen D, Guisez Y. Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit. Clin Vaccine Immunol 2008;15:852-8. [PMID: 18367580 DOI: 10.1128/CVI.00382-07] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
51 Basu R, Zhai L, Contreras A, Tumban E. Immunization with phage virus-like particles displaying Zika virus potential B-cell epitopes neutralizes Zika virus infection of monkey kidney cells. Vaccine 2018;36:1256-64. [PMID: 29395533 DOI: 10.1016/j.vaccine.2018.01.056] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
52 Vanlandschoot P, Van Houtte F, Serruys B, Leroux-Roels G. Contamination of a recombinant hepatitis B virus nucleocapsid preparation with a human B-cell activator. J Virol 2007;81:2535-6. [PMID: 17151106 DOI: 10.1128/JVI.02507-06] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
53 Jiang B, Hildt E. Intracellular Trafficking of HBV Particles. Cells 2020;9:E2023. [PMID: 32887393 DOI: 10.3390/cells9092023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
54 Berardi A, Lomonossoff GP, Evans DJ, Barker SA. Plant-expressed Hepatitis B core antigen virus-like particles: Characterization and investigation of their stability in simulated and pig gastro-intestinal fluids. Int J Pharm 2017;522:147-56. [PMID: 28263835 DOI: 10.1016/j.ijpharm.2017.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
55 Billaud JN, Peterson D, Lee BO, Maruyama T, Chen A, Sallberg M, Garduño F, Goldstein P, Hughes J, Jones J. Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms. Vaccine. 2007;25:1593-1606. [PMID: 17178179 DOI: 10.1016/j.vaccine.2006.11.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
56 Kutscher S, Bauer T, Dembek C, Sprinzl M, Protzer U. Design of therapeutic vaccines: hepatitis B as an example. Microb Biotechnol 2012;5:270-82. [PMID: 21958338 DOI: 10.1111/j.1751-7915.2011.00303.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
57 Ma Y, Hayglass KT, Becker AB, Halayko AJ, Basu S, Simons FE, Peng Z. Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice. Allergy 2007;62:675-82. [PMID: 17508973 DOI: 10.1111/j.1398-9995.2007.01384.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
58 Li J, Bao M, Ge J, Ren S, Zhou T, Qi F, Pu X, Dou J. Research progress of therapeutic vaccines for treating chronic hepatitis B. Hum Vaccin Immunother 2017;13:986-97. [PMID: 28118084 DOI: 10.1080/21645515.2016.1276125] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
59 Ma Y, HayGlass KT, Becker AB, Fan Y, Yang X, Basu S, Srinivasan G, Simons FE, Halayko AJ, Peng Z. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am J Respir Crit Care Med 2007;176:439-45. [PMID: 17556715 DOI: 10.1164/rccm.200610-1405OC] [Cited by in Crossref: 44] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
60 Yin Y, Zhang S, Cai C, Zhang J, Dong D, Guo Q, Fu L, Xu J, Chen W. Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine. Immunobiology 2014;219:97-103. [PMID: 24054942 DOI: 10.1016/j.imbio.2013.08.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
61 Chackerian B, Remaley A. Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9. Curr Opin Lipidol 2016;27:345-50. [PMID: 27389630 DOI: 10.1097/MOL.0000000000000312] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
62 Chen M, Sallberg M, Thung SN, Hughes J, Jones J, Milich DR. Modeling the T-helper cell response in acute and chronic hepatitis B virus infection using T-cell receptor transgenic mice. Antiviral Res. 2001;52:99-111. [PMID: 11672819 DOI: 10.1016/S0166-3542(01)00174-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
63 Huang LR, Wu HL, Chen PJ, Chen DS. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci USA. 2006;103:17862-17867. [PMID: 17095599 DOI: 10.1073/pnas.0608578103] [Cited by in Crossref: 190] [Cited by in F6Publishing: 185] [Article Influence: 12.7] [Reference Citation Analysis]
64 Krauskopf J, de Kok TM, Schomaker SJ, Gosink M, Burt DA, Chandler P, Warner RL, Johnson KJ, Caiment F, Kleinjans JC, Aubrecht J. Serum microRNA signatures as "liquid biopsies" for interrogating hepatotoxic mechanisms and liver pathogenesis in human. PLoS One. 2017;12:e0177928. [PMID: 28545106 DOI: 10.1371/journal.pone.0177928] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
65 Fam SY, Chee CF, Yong CY, Ho KL, Mariatulqabtiah AR, Lau HY, Tan WS. Shielding of Hepatitis B Virus-Like Nanoparticle with Poly(2-Ethyl-2-Oxazoline). Int J Mol Sci 2019;20:E4903. [PMID: 31623310 DOI: 10.3390/ijms20194903] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Fuller DH, Shipley T, Allen TM, Fuller JT, Wu MS, Horton H, Wilson N, Widera G, Watkins DI. Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques. Virology 2007;364:245-55. [PMID: 17428516 DOI: 10.1016/j.virol.2007.02.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
67 Golsaz-Shirazi F, Shokri F. Hepatitis B immunopathogenesis and immunotherapy. Immunotherapy. 2016;8:461-477. [PMID: 26973127 DOI: 10.2217/imt.16.3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
68 Guo YH, Hao ZM, Luo JY, Wang JH. Construction of prokaryotic expression system of TGF-beta1 epitope gene and identification of recombinant fusion protein immunity. World J Gastroenterol. 2005;11:6389-6394. [PMID: 16419171 DOI: 10.3748/wjg.v11.i40.6389] [Reference Citation Analysis]
69 Chen H, Lü JH, Liang WQ, Huang YH, Zhang WJ, Zhang DB. Purification of the recombinant hepatitis B virus core antigen (rHBcAg) produced in the yeast Saccharomyces cerevisiae and comparative observation of its particles by transmission electron microscopy (TEM) and atomic force microscopy (AFM). Micron 2004;35:311-8. [PMID: 15006357 DOI: 10.1016/j.micron.2003.12.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
70 Sung FY, Jung CM, Wu CF, Lin CL, Liu CJ, Liaw YF, Tsai KS, Yu MW. Hepatitis B virus core variants modify natural course of viral infection and hepatocellular carcinoma progression. Gastroenterology. 2009;137:1687-1697. [PMID: 19664630 DOI: 10.1053/j.gastro.2009.07.063] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
71 Pumpens P, Grens E. The true story and advantages of the famous Hepatitis B virus core particles: Outlook 2016. Mol Biol 2016;50:489-509. [DOI: 10.1134/s0026893316040099] [Cited by in Crossref: 10] [Article Influence: 2.0] [Reference Citation Analysis]
72 Beterams G, Böttcher B, Nassal M. Packaging of up to 240 subunits of a 17 kDa nuclease into the interior of recombinant hepatitis B virus capsids. FEBS Letters 2000;481:169-76. [DOI: 10.1016/s0014-5793(00)01927-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
73 Dong YM, Zhang GG, Huang XJ, Chen L, Chen HT. Promising MS2 mediated virus-like particle vaccine against foot-and-mouth disease. Antiviral Res 2015;117:39-43. [PMID: 25676866 DOI: 10.1016/j.antiviral.2015.01.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
74 Li R, Bar-Or A. The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies. Cold Spring Harb Perspect Med 2019;9:a029108. [PMID: 29661809 DOI: 10.1101/cshperspect.a029108] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
75 Loggi E, Gamal N, Bihl F, Bernardi M, Andreone P. Adaptive response in hepatitis B virus infection. J Viral Hepat. 2014;21:305-313. [PMID: 24674098 DOI: 10.1111/jvh.12255] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
76 Li ZX, Hong GQ, Hu B, Liang MJ, Xu J, Li L. Suitability of yeast- and Escherichia coli-expressed hepatitis B virus core antigen derivatives for detection of anti-HBc antibodies in human sera. Protein Expr Purif. 2007;56:293-300. [PMID: 17897838 DOI: 10.1016/j.pep.2007.08.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
77 Ferrari C, Missale G, Boni C, Urbani S. Immunopathogenesis of hepatitis B. J Hepatol. 2003;39 Suppl 1:S36-S42. [PMID: 14708676 DOI: 10.1016/s0168-8278(03)00137-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
78 Watelet B, Quibriac M, Rolland D, Gervasi G, Gauthier M, Jolivet M, Letourneur O. Erratum to “Characterization and diagnostic potential of hepatitis B virus nucleocapsid expressed in E. coli and P. pastoris”. Journal of Virological Methods 2002;102:175-90. [DOI: 10.1016/s0166-0934(02)00003-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Skamel C, Ploss M, Böttcher B, Stehle T, Wallich R, Simon MM, Nassal M. Hepatitis B virus capsid-like particles can display the complete, dimeric outer surface protein C and stimulate production of protective antibody responses against Borrelia burgdorferi infection. J Biol Chem. 2006;281:17474-17481. [PMID: 16621801 DOI: 10.1074/jbc.M513571200] [Cited by in Crossref: 39] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
80 Revill P, Locarnini S. The Basis for Antiviral Therapy: Drug Targets, Cross-Resistance, and Novel Small Molecule Inhibitors. In: Liaw Y, Zoulim F, editors. Hepatitis B Virus in Human Diseases. Cham: Springer International Publishing; 2016. pp. 303-24. [DOI: 10.1007/978-3-319-22330-8_14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
81 Chou SF, Tsai ML, Huang JY, Chang YS, Shih C. The Dual Role of an ESCRT-0 Component HGS in HBV Transcription and Naked Capsid Secretion. PLoS Pathog 2015;11:e1005123. [PMID: 26431433 DOI: 10.1371/journal.ppat.1005123] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
82 Denis J, Majeau N, Acosta-Ramirez E, Savard C, Bedard MC, Simard S, Lecours K, Bolduc M, Pare C, Willems B, Shoukry N, Tessier P, Lacasse P, Lamarre A, Lapointe R, Lopez Macias C, Leclerc D. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology 2007;363:59-68. [PMID: 17320136 DOI: 10.1016/j.virol.2007.01.011] [Cited by in Crossref: 95] [Cited by in F6Publishing: 90] [Article Influence: 6.8] [Reference Citation Analysis]
83 Chang WW, Su IJ, Lai MD, Chang WT, Huang W, Lei HY. The role of inducible nitric oxide synthase in a murine acute hepatitis B virus (HBV) infection model induced by hydrodynamics-based in vivo transfection of HBV-DNA. J Hepatol. 2003;39:834-842. [PMID: 14568268 DOI: 10.1016/s0168-8278(03)00389-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
84 Heyman B. IgE-mediated enhancement of antibody responses: the beneficial function of IgE? Allergy 2002;57:577-85. [PMID: 12100297 DOI: 10.1034/j.1398-9995.2002.02159.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
85 Hjelm F, Karlsson MCI, Heyman B. A Novel B Cell-Mediated Transport of IgE-Immune Complexes to the Follicle of the Spleen. J Immunol 2008;180:6604-10. [DOI: 10.4049/jimmunol.180.10.6604] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
86 Lee SY, Choi MS, Lee D, Lee JH, Koh KC, Paik SW, Yoo BC. Overlapping gene mutations of hepatitis B virus in a chronic hepatitis B patient with hepatitis B surface antigen loss during lamivudine therapy. J Korean Med Sci 2005;20:433-7. [PMID: 15953865 DOI: 10.3346/jkms.2005.20.3.433] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
87 Böttcher B. Hepatitis B Core Protein Capsids. Subcell Biochem 2021;96:451-70. [PMID: 33252740 DOI: 10.1007/978-3-030-58971-4_14] [Reference Citation Analysis]
88 Zhou Z, Hu T, Zhou X, Wildum S, Garcia-Alcalde F, Xu Z, Wu D, Mao Y, Tian X, Zhou Y, Shen F, Zhang Z, Tang G, Najera I, Yang G, Shen HC, Young JA, Qin N. Heteroaryldihydropyrimidine (HAP) and Sulfamoylbenzamide (SBA) Inhibit Hepatitis B Virus Replication by Different Molecular Mechanisms. Sci Rep 2017;7:42374. [PMID: 28205569 DOI: 10.1038/srep42374] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 14.3] [Reference Citation Analysis]
89 Buchmann P, Dembek C, Kuklick L, Jäger C, Tedjokusumo R, von Freyend MJ, Drebber U, Janowicz Z, Melber K, Protzer U. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 2013;31:1197-203. [DOI: 10.1016/j.vaccine.2012.12.074] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 8.0] [Reference Citation Analysis]
90 Birkett A, Lyons K, Schmidt A, Boyd D, Oliveira GA, Siddique A, Nussenzweig R, Calvo-Calle JM, Nardin E. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect Immun 2002;70:6860-70. [PMID: 12438363 DOI: 10.1128/IAI.70.12.6860-6870.2002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
91 Chaperot L, Jacob M, Molens J, Manches O, Bensa J, Plumas J. From the Study of Tumor Cell Immunogenicity to the Generation of Antitumor Cytotoxic Cells in Non-Hodgkin's Lymphomas. Leukemia & Lymphoma 2009;38:247-63. [DOI: 10.3109/10428190009087016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
92 Caballero A, Tabernero D, Buti M, Rodriguez-Frias F. Hepatitis B virus: The challenge of an ancient virus with multiple faces and a remarkable replication strategy. Antiviral Res 2018;158:34-44. [PMID: 30059722 DOI: 10.1016/j.antiviral.2018.07.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
93 Nassal M, Skamel C, Vogel M, Kratz PA, Stehle T, Wallich R, Simon MM. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines. Int J Med Microbiol 2008;298:135-42. [PMID: 17888729 DOI: 10.1016/j.ijmm.2007.08.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
94 Lin YJ, Huang LR, Yang HC, Tzeng HT, Hsu PN, Wu HL, Chen PJ, Chen DS. Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model. Proc Natl Acad Sci USA. 2010;107:9340-9345. [PMID: 20439715 DOI: 10.1073/pnas.1004762107] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 5.3] [Reference Citation Analysis]
95 O'Rourke JP, Peabody DS, Chackerian B. Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform. Curr Opin Virol 2015;11:76-82. [PMID: 25829254 DOI: 10.1016/j.coviro.2015.03.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
96 Getahun A, Heyman B. IgG- and IgE-mediated antigen presentation on MHC class II. Immunol Lett 2004;92:33-8. [PMID: 15081524 DOI: 10.1016/j.imlet.2003.09.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
97 Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, Alberts E, Davidson BR, Kennedy PT, Gill US, Mauri C, Blair PA, Pelletier N, Maini MK. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest. 2018;128:4588-4603. [PMID: 30091725 DOI: 10.1172/jci121960] [Cited by in Crossref: 103] [Cited by in F6Publishing: 57] [Article Influence: 34.3] [Reference Citation Analysis]
98 Diepolder HM, Ries G, Jung MC, Schlicht HJ, Gerlach JT, Gr ner N, Caselmann WH, Pape GR. Differential antigen-processing pathways of the hepatitis B virus e and core proteins. Gastroenterology. 1999;116:650-657. [PMID: 10029624 DOI: 10.1016/s0016-5085(99)70187-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
99 Vogel M, Vorreiter J, Nassal M. Quaternary structure is critical for protein display on capsid-like particles (CLPs): Efficient generation of hepatitis B virus CLPs presenting monomeric but not dimeric and tetrameric fluorescent proteins. Proteins 2005;58:478-88. [DOI: 10.1002/prot.20312] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
100 Su Q, Yi Y, Guo M, Qiu F, Jia Z, Lu X, Meng Q, Bi S. Construction and immunological evaluation of truncated hepatitis B core particles carrying HBsAg amino acids 119-152 in the major immunodominant region (MIR). Biochem Biophys Res Commun 2013;439:84-9. [PMID: 23969156 DOI: 10.1016/j.bbrc.2013.08.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
101 Bardens A, Döring T, Stieler J, Prange R. Alix regulates egress of hepatitis B virus naked capsid particles in an ESCRT-independent manner. Cell Microbiol 2011;13:602-19. [PMID: 21129143 DOI: 10.1111/j.1462-5822.2010.01557.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
102 Getahun A, Hjelm F, Heyman B. IgE Enhances Antibody and T Cell Responses In Vivo via CD23 + B Cells. J Immunol 2005;175:1473-82. [DOI: 10.4049/jimmunol.175.3.1473] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 4.2] [Reference Citation Analysis]
103 Wu C, Liu Y, Zhao Q, Chen G, Chen J, Yan X, Zhou YH, Huang Z. Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy. Virol J 2010;7:370. [PMID: 21176236 DOI: 10.1186/1743-422X-7-370] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
104 Yuan Q, Song LW, Cavallone D, Moriconi F, Cherubini B, Colombatto P, Oliveri F, Coco BA, Ricco G, Bonino F, Shih JW, Xia NS, Brunetto MR. Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease. PLoS One 2015;10:e0130209. [PMID: 26115521 DOI: 10.1371/journal.pone.0130209] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
105 Maini MK, Burton AR. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nat Rev Gastroenterol Hepatol. 2019;16:662-675. [PMID: 31548710 DOI: 10.1038/s41575-019-0196-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 16.5] [Reference Citation Analysis]
106 Cai Y, Yin W. The Multiple Functions of B Cells in Chronic HBV Infection. Front Immunol 2020;11:582292. [PMID: 33381113 DOI: 10.3389/fimmu.2020.582292] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
107 Kumar S, Ochoa W, Singh P, Hsu C, Schneemann A, Manchester M, Olson M, Reddy V. Tomato bushy stunt virus (TBSV), a versatile platform for polyvalent display of antigenic epitopes and vaccine design. Virology 2009;388:185-90. [PMID: 19344926 DOI: 10.1016/j.virol.2009.02.051] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
108 Chen M, Sällberg M, Sönnerborg A, Weiland O, Mattsson L, Jin L, Birkett A, Peterson D, Milich DR. Limited humoral immunity in hepatitis C virus infection. Gastroenterology. 1999;116:135-143. [PMID: 9869611 DOI: 10.1016/s0016-5085(99)70237-4] [Cited by in Crossref: 119] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
109 Grob P, Jilg W, Bornhak H, Gerken G, Gerlich W, G�nther S, Hess G, H�dig H, Kitchen A, Margolis H, Michel G, Trepo C, Will H, Zanetti A, Mushahwar I. Serological pattern ?anti-HBc alone?: Report on a workshop. J Med Virol 2000;62:450-5. [DOI: 10.1002/1096-9071(200012)62:4<450::aid-jmv9>3.0.co;2-y] [Cited by in Crossref: 161] [Cited by in F6Publishing: 44] [Article Influence: 7.7] [Reference Citation Analysis]
110 Bose B, Khanna N, Acharya SK, Sinha S. High affinity mouse-human chimeric Fab against hepatitis B surface antigen. World J Gastroenterol 2005;11:7569-78. [PMID: 16437680 DOI: 10.3748/wjg.v11.i48.7569] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
111 Billaud JN, Peterson D, Barr M, Chen A, Sallberg M, Garduno F, Goldstein P, McDowell W, Hughes J, Jones J, Milich D. Combinatorial approach to hepadnavirus-like particle vaccine design. J Virol 2005;79:13656-66. [PMID: 16227285 DOI: 10.1128/JVI.79.21.13656-13666.2005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
112 Guan Q, Ma Y, Hillman CL, Ma A, Zhou G, Qing G, Peng Z. Development of recombinant vaccines against IL-12/IL-23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis. Vaccine 2009;27:7096-104. [PMID: 19786142 DOI: 10.1016/j.vaccine.2009.09.058] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
113 Brahmania M, Feld J, Arif A, Janssen HL. New therapeutic agents for chronic hepatitis B. Lancet Infect Dis 2016;16:e10-21. [PMID: 26795693 DOI: 10.1016/S1473-3099(15)00436-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
114 Wang K, Pei H, Huang B, Yang RL, Wu HY, Zhu X, Zhu L. Overexpression of Fc receptor-like 1 associated with B-cell activation during hepatitis B virus infection. Braz J Med Biol Res 2012;45:1112-8. [PMID: 22892829 DOI: 10.1590/s0100-879x2012007500130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
115 Pumpens P, Grens E. Hepatitis B core particles as a universal display model: a structure-function basis for development. FEBS Lett. 1999;442:1-6. [PMID: 9923592 DOI: 10.1016/s0014-5793(98)01599-3] [Cited by in Crossref: 76] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
116 Vanlandschoot P, Van Houtte F, Serruys B, Leroux-Roels G. The arginine-rich carboxy-terminal domain of the hepatitis B virus core protein mediates attachment of nucleocapsids to cell-surface-expressed heparan sulfate. J Gen Virol 2005;86:75-84. [PMID: 15604433 DOI: 10.1099/vir.0.80580-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
117 Hua Z, Hou B. The role of B cell antigen presentation in the initiation of CD4+ T cell response. Immunol Rev 2020;296:24-35. [PMID: 32304104 DOI: 10.1111/imr.12859] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
118 Arzberger S, Hösel M, Protzer U. Apoptosis of hepatitis B virus-infected hepatocytes prevents release of infectious virus. J Virol 2010;84:11994-2001. [PMID: 20719950 DOI: 10.1128/JVI.00653-10] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
119 Chen MT, Billaud JN, Sällberg M, Guidotti LG, Chisari FV, Jones J, Hughes J, Milich DR. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci USA. 2004;101:14913-14918. [PMID: 15469922 DOI: 10.1073/pnas.0406282101] [Cited by in Crossref: 175] [Cited by in F6Publishing: 153] [Article Influence: 10.3] [Reference Citation Analysis]
120 Cao T, Lazdina U, Desombere I, Vanlandschoot P, Milich DR, Sällberg M, Leroux-Roels G. Hepatitis B virus core antigen binds and activates naive human B cells in vivo: studies with a human PBL-NOD/SCID mouse model. J Virol. 2001;75:6359-6366. [PMID: 11413302 DOI: 10.1128/JVI.75.14.6359-6366.2001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
121 Strods A, Ose V, Bogans J, Cielens I, Kalnins G, Radovica I, Kazaks A, Pumpens P, Renhofa R. Preparation by alkaline treatment and detailed characterisation of empty hepatitis B virus core particles for vaccine and gene therapy applications. Sci Rep 2015;5:11639. [PMID: 26113394 DOI: 10.1038/srep11639] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
122 Lu B, Zhang B, Wang L, Ma C, Liu X, Zhao Y, Jiao Y. Hepatitis B Virus e Antigen Regulates Monocyte Function and Promotes B Lymphocyte Activation. Viral Immunol 2017;30:35-44. [PMID: 27976981 DOI: 10.1089/vim.2016.0113] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
123 Milich DR, Hughes J, Jones J, Sällberg M, Phillips TR. Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate. Vaccine. 2001;20:771-788. [PMID: 11738741 DOI: 10.1016/s0264-410x(01)00400-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
124 Cho HJ, Cheong JY. Role of Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Int J Mol Sci 2021;22:8011. [PMID: 34360777 DOI: 10.3390/ijms22158011] [Reference Citation Analysis]
125 Milich DR. Do T cells “see” the hepatitis B core and e antigens differently? Gastroenterology. 1999;116:765-768. [PMID: 10029635 DOI: 10.1016/s0016-5085(99)70203-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
126 Aguilar JC, Lobaina Y, Muzio V, García D, Pentón E, Iglesias E, Pichardo D, Urquiza D, Rodríguez D, Silva D, Petrovsky N, Guillén G. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol 2004;82:539-46. [PMID: 15479440 DOI: 10.1111/j.0818-9641.2004.01278.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
127 Chen H, Liu S, Chen L, Huang J, Xiang S. Expression of HBcAg mutant with long internal deletion in Saccharomyces cerevisiae and observation of its self-assembly particles by atomic force microscopy (AFM). International Journal of Biological Macromolecules 2005;37:239-48. [DOI: 10.1016/j.ijbiomac.2005.12.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
128 Chi H, Li Z, Hansen BE, Yu T, Zhang X, Sun J, Hou J, Janssen HLA, Peng J. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy. Clin Gastroenterol Hepatol 2019;17:182-191.e1. [PMID: 29902645 DOI: 10.1016/j.cgh.2018.05.047] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
129 Rivera A, Chen C, Ron N, Dougherty JP, Ron Y. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. International Immunology 2001;13:1583-93. [DOI: 10.1093/intimm/13.12.1583] [Cited by in Crossref: 126] [Cited by in F6Publishing: 115] [Article Influence: 6.3] [Reference Citation Analysis]
130 Li J, Ge J, Ren S, Zhou T, Sun Y, Sun H, Gu Y, Huang H, Xu Z, Chen X, Xu X, Zhuang X, Song C, Jia F, Xu A, Yin X, Du SX. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection. Vaccine 2015;33:4247-54. [PMID: 25858855 DOI: 10.1016/j.vaccine.2015.03.079] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
131 DiMattia MA, Watts NR, Stahl SJ, Grimes JM, Steven AC, Stuart DI, Wingfield PT. Antigenic switching of hepatitis B virus by alternative dimerization of the capsid protein. Structure 2013;21:133-42. [PMID: 23219881 DOI: 10.1016/j.str.2012.10.017] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
132 Burton AR, Maini MK. Human antiviral B cell responses: Emerging lessons from hepatitis B and COVID-19. Immunol Rev 2021;299:108-17. [PMID: 33559128 DOI: 10.1111/imr.12953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
133 Lobaina Y, García D, Abreu N, Muzio V, Aguilar JC. Mucosal immunogenicity of the hepatitis B core antigen. Biochem Biophys Res Commun. 2003;300:745-750. [PMID: 12507513 DOI: 10.1016/s0006-291x(02)02897-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
134 Miller MA, Ganesan AP, Eisenlohr LC. Toward a Network Model of MHC Class II-Restricted Antigen Processing. Front Immunol 2013;4:464. [PMID: 24379819 DOI: 10.3389/fimmu.2013.00464] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
135 Fu Y, Li J. A novel delivery platform based on Bacteriophage MS2 virus-like particles. Virus Res 2016;211:9-16. [PMID: 26415756 DOI: 10.1016/j.virusres.2015.08.022] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
136 Lobaina Y, Hardtke S, Wedemeyer H, Aguilar JC, Schlaphoff V. In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol. 2015;63:320-327. [PMID: 25193323 DOI: 10.1016/j.molimm.2014.08.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
137 Nassal M, Skamel C, Kratz PA, Wallich R, Stehle T, Simon MM. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula. Eur J Immunol. 2005;35:655-665. [PMID: 15668917 DOI: 10.1002/eji.200425449] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.6] [Reference Citation Analysis]
138 Günther S, Fischer L, Pult I, Sterneck M, Will H. Naturally Occurring Variants of Hepatitis B Virus. Elsevier; 1999. pp. 25-137. [DOI: 10.1016/s0065-3527(08)60298-5] [Cited by in Crossref: 172] [Cited by in F6Publishing: 54] [Article Influence: 7.8] [Reference Citation Analysis]
139 Ding F, Xian X, Guo Y, Liu Y, Wang Y, Yang F, Wang Y, Song S, Wang F, Sun S. A preliminary study on the activation and antigen presentation of hepatitis B virus core protein virus-like particle-pulsed bone marrow-derived dendritic cells. Mol BioSyst 2010;6:2192. [DOI: 10.1039/c005222a] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]